Akero Therapeutics, Inc. (NASDAQ:AKRO) CTO Scott A. Gangloff Sells 848 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CTO Scott A. Gangloff sold 848 shares of Akero Therapeutics stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $54.84, for a total value of $46,504.32. Following the completion of the transaction, the chief technology officer now owns 23,452 shares in the company, valued at approximately $1,286,107.68. This represents a 3.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Akero Therapeutics Price Performance

Shares of Akero Therapeutics stock traded down $0.17 on Monday, reaching $54.03. The stock had a trading volume of 1,271,985 shares, compared to its average volume of 1,014,119. The business's 50 day moving average is $45.88 and its two-hundred day moving average is $41.25. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. Akero Therapeutics, Inc. has a 1 year low of $21.02 and a 1 year high of $58.40. The company has a market cap of $4.31 billion, a P/E ratio of -27.71 and a beta of -0.16.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. As a group, research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Institutional Investors Weigh In On Akero Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC grew its position in shares of Akero Therapeutics by 302.9% in the 1st quarter. Voya Investment Management LLC now owns 82,471 shares of the company's stock worth $3,338,000 after buying an additional 62,000 shares during the last quarter. Rhumbline Advisers lifted its stake in Akero Therapeutics by 4.7% in the first quarter. Rhumbline Advisers now owns 110,687 shares of the company's stock worth $4,481,000 after acquiring an additional 5,001 shares during the period. Strs Ohio bought a new stake in Akero Therapeutics in the first quarter valued at $510,000. Intech Investment Management LLC boosted its holdings in Akero Therapeutics by 54.4% in the first quarter. Intech Investment Management LLC now owns 58,522 shares of the company's stock valued at $2,369,000 after acquiring an additional 20,620 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Akero Therapeutics by 53.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 109,909 shares of the company's stock valued at $4,449,000 after purchasing an additional 38,458 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Bank of America raised their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a report on Tuesday, May 27th. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. HC Wainwright lifted their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Finally, Citigroup decreased their price objective on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Akero Therapeutics has a consensus rating of "Buy" and an average target price of $82.50.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.